Impact Journals, the publisher of Aging, is once again proudly sponsoring the Open Access Team in the annual Ride for Roswell.
Aging (Aging-US) Authors
Aging (Aging-US) is pleased to announce a special Call for Papers for a commemorative collection honoring the legacy of Dr. Mikhail (Misha) Blagosklonny, the founding editor of the journal and a pioneer in aging biology. His groundbreaking work shaped fundamental concepts in the field, particularly regarding the role of mTOR in aging and cancer, the use of rapamycin, bypassing senescence during the process of transformation, personalized medicine, and theories on why we age.
The untimely passing of Dr. Mikhail “Misha” Blagosklonny has left a lasting void in geroscience and oncology. This review examines his profound contributions, focusing on his pioneering the Hyperfunction Theory and his advocacy for rapamycin, an mTOR inhibitor, as a therapeutic agent for lifespan extension.
A new priority review was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) on January 12, 2025, entitled “Mikhail ‘Misha’ Blagosklonny’s enduring legacy in geroscience: the hyperfunction theory and the therapeutic potential of rapamycin.”
Drs. Alex Zhavoronkov, Morten Scheibye-Knudsen, Evelyne Bischof and Dominika Wilczok discuss a research paper they co-authored that was published by Aging, entitled, “Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity.”
It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
PRESS RELEASE – On July 28, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new editorial in Volume 16, Issue 14 of Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science), entitled, “Targeted cancer therapy: the initial high concentration may slow down the selection for resistance.”
PRESS RELEASE: On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., published a new brief report in Oncoscience, entitled, “My battle with cancer. Part 1.”
Dr. Mikhail Blagosklonny joins “Master One Thing” host Krister Kauppi to discuss the impact of his rapamycin research and hyperfunciton theory of aging.
PRESS RELEASE: A new research perspective was published in Aging’s Volume 15, Issue 14, entitled, “Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?”